started · updated
New medical studies examine gestational diabetes and GLP-1 RA efficacy
Recent medical analyses have provided new insights into the management of gestational diabetes and the impact of GLP-1 receptor agonists (GLP-1 RAs) on liver disease.
A reanalysis of the Early Metformin in Gestational Diabetes (EMERGE) trial, published in JAMA Network Open, suggests that starting metformin early in patients with gestational diabetes may reduce the need for insulin. Using generalized pairwise comparisons, researchers found that metformin produced more favorable outcomes regarding insulin initiation and fasting hyperglycemia compared to a placebo.
Additionally, a national analysis presented to the American Heart Association indicates that a history of gestational diabetes is linked to more advanced cardiovascular-kidney-metabolic (CKM) syndrome in women aged 30 to 79.
In a separate systematic review published in Medicine, researchers found that GLP-1 RAs are associated with improvements in hepatic steatosis, liver enzymes, body weight, and glycated hemoglobin in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH). While these drugs show promise in improving liver and metabolic markers, the study noted that long-term benefits remain unproven and there is a continued unmet need for therapies targeting both metabolic dysfunction and fibrotic progression.
Entities
American Heart Association · FDA · JAMA Network Open · Madrigal Pharmaceuticals · Novo Nordisk